Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2026)

Xeris Biopharma Holdings' Gross Margin history runs 7 years deep, the most recent figure standing at 87.28% for Q1 2026.

• Quarterly Gross Margin rose 180.0% year-over-year to 87.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.89% (up 368.0% YoY) and the FY2025 annual result came in at 85.41%, up 355.0% from the prior year.
• Gross Margin was 87.28% for Q1 2026 at Xeris Biopharma Holdings, roughly flat from 87.24% in the prior quarter.
• Across five years, Gross Margin topped out at 87.28% in Q1 2026 and bottomed at 71.58% in Q1 2022.
• A 5-year average of 82.52% and a median of 83.37% in 2025 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2022 — Gross Margin surged 1898 bps — and 2024, when it slumped 808 bps.
• Xeris Biopharma Holdings' Gross Margin stood at 81.02% in 2022, then gained by 2 bps to 82.95% in 2023, then climbed by 2 bps to 84.23% in 2024, then increased by 4 bps to 87.24% in 2025, then rose by 0 bps to 87.28% in 2026.
• Business Quant data shows XERS's Gross Margin at 87.28% in Q1 2026, 87.24% in Q4 2025, and 85.22% in Q3 2025.